Information Provided By: 
Fly News Breaks for January 17, 2020
TGTX
Jan 17, 2020 | 08:51 EDT
B. Riley FBR analyst Mayank Mamtani raised his price target for TG Therapeutics to $25 from $17 after the company initiaied a rolling new drug application for two hematologic malignancies after recently receiving guidance from the FDA that a single NDA for both indications would be acceptable to allow accelerated approval. The analyst continues to believe in "substantial equity upside," citing the de-risked nature of several clinical and regulatory catalysts through 2020. He reiterates a Buy rating on the shares.
News For TGTX From the Last 2 Days
There are no results for your query TGTX
